These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25334045)

  • 1. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
    Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
    Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
    Cid J
    Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions.
    Hamzeh-Cognasse H; Damien P; Nguyen KA; Arthaud CA; Eyraud MA; Chavarin P; Absi L; Osselaer JC; Pozzetto B; Cognasse F; Garraud O
    Transfusion; 2014 Mar; 54(3):613-25. PubMed ID: 23944651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
    Knutson F; Osselaer J; Pierelli L; Lozano M; Cid J; Tardivel R; Garraud O; Hervig T; Domanovic D; Cukjati M; Gudmundson S; Hjalmarsdottir IB; Castrillo A; Gonzalez R; Brihante D; Santos M; Schlenke P; Elliott A; Lin JS; Tappe D; Stassinopoulos A; Green J; Corash L
    Vox Sang; 2015 Nov; 109(4):343-52. PubMed ID: 25981525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
    Sandgren P; Diedrich B
    Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
    Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
    Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
    Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
    Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
    Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
    Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
    Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
    Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
    Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
    Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
    Arnason NA; Johannson F; Landrö R; Hardarsson B; Irsch J; Gudmundsson S; Rolfsson O; Sigurjonsson OE
    Transfusion; 2019 Dec; 59(12):3727-3735. PubMed ID: 31674051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
    Girard YA; Santa Maria F; Lanteri MC
    Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
    Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
    Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
    Amato M; Schennach H; Astl M; Chen CY; Lin JS; Benjamin RJ; Nussbaumer W
    Vox Sang; 2017 Jan; 112(1):47-55. PubMed ID: 28001297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers.
    Cognasse F; Aloui C; Anh Nguyen K; Hamzeh-Cognasse H; Fagan J; Arthaud CA; Eyraud MA; Sebban M; Fromont E; Pozzetto B; Laradi S; Garraud O
    Transfusion; 2016 Feb; 56(2):497-504. PubMed ID: 26446055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro.
    Van Aelst B; Feys HB; Devloo R; Vanhoorelbeke K; Vandekerckhove P; Compernolle V
    Vox Sang; 2015 May; 108(4):328-39. PubMed ID: 25557250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
    Cazenave JP
    Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
    Stivala S; Gobbato S; Infanti L; Reiner MF; Bonetti N; Meyer SC; Camici GG; Lüscher TF; Buser A; Beer JH
    Haematologica; 2017 Oct; 102(10):1650-1660. PubMed ID: 28729303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
    Reid S; Johnson L; Woodland N; Marks DC
    Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
    Slichter SJ; Bailey SL; Gettinger I; Pellham E; Christoffel T; Castro G; Green JM; Stassinopoulos A
    Vox Sang; 2019 Aug; 114(6):595-604. PubMed ID: 31297836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.